{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:30:40Z","timestamp":1786649440426,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>Data on occurrence of pneumothorax after the use of oral pazopanib in advanced soft tissue sarcoma (STS) with lung metastases are scarce in literature. We aimed to evaluate those in our patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This was a single center retrospective study of incidence of pneumothorax in patients with lung metastases in advanced STS treated with oral pazopanib between July, 2016 and December, 2020. Patients were treated with pazopanib usually from 2\n                      <jats:sup>nd<\/jats:sup>\n                      line onwards with a dose ranging from 400 mg to 800 mg once daily.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Total of 34 patients with lung metastasis in a setting of advanced STS were treated with oral pazopanib during the study period. The setting of pazopanib use was 2\n                      <jats:sup>nd<\/jats:sup>\n                      line in four and 1\n                      <jats:sup>st<\/jats:sup>\n                      line in one of them. The starting dose was 600 mg once daily in three patients, 400 mg OD in one patient, and 800 mg OD in one patient. Five patients developed pneumothorax with duration on pazopanib of 6, 7, 24, 6, and 2.5 months, respectively. Three patients had symptoms and required chest tube drainage. None of them were smokers or had any other underlying lung disease. The disease response of those patients was stable disease in four and partial response in one during treatment with pazopanib. One patient had a rechallenge with further pazopanib course without any recurrence of pneumothorax.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Pneumothorax is a rare pulmonary complication after pazopanib use in patients with lung metastasis. Clinicians should be aware of this rare complication as literature is scarce. Rechallenge with pazopanib is feasible after pneumothorax.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_95_21","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T02:00:09Z","timestamp":1693879209000},"page":"278-281","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pneumothorax in lung metastasis of advanced soft tissue sarcoma patients treated with oral pazopanib"],"prefix":"10.4103","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-0370","authenticated-orcid":false,"given":"Sayan","family":"Sarkar","sequence":"first","affiliation":[{"name":"Department of Radiology and Imaging, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4341-8900","authenticated-orcid":false,"given":"Pradipta Kumar","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8997-2495","authenticated-orcid":false,"given":"Sumit","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-712X","authenticated-orcid":false,"given":"Saugata","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6101-5500","authenticated-orcid":false,"given":"Bivas","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"R1-20260426","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-019-0049-6","article-title":"Pazopanib in advanced soft tissue sarcomas","volume":"4","author":"Lee","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"R2-20260426","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"R3-20260426","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1186\/s12885-019-5988-3","article-title":"Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses","volume":"19","author":"Cesne","year":"2019","journal-title":"BMC Cancer"},{"key":"R4-20260426","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1148\/rg.2017170015","article-title":"Thoracic complications of precision cancer therapies: A practical guide for radiologists in the new era of cancer care","volume":"37","author":"Nishino","year":"2017","journal-title":"Radiographics"},{"key":"R5-20260426","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2008.16.2545","article-title":"Tumor cavitation: Impact on objective response evaluation in trials of angiogenesis inhibitors in non\u2013small-cell lung cancer","volume":"27","author":"Crabb","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-20260426","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000463380","article-title":"Pneumothorax during pazopanib treatment in patients with soft-tissue sarcoma: Two case reports and a review of the literature","volume":"10","author":"Nakahara","year":"2017","journal-title":"Case Rep Oncol"},{"key":"R7-20260426","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1186\/s12885-016-2786-z","article-title":"Risk factors for pneumothorax in advanced and\/or metastatic soft tissue sarcoma patients during pazopanib treatment: A single-institute analysis","volume":"16","author":"Nakano","year":"2016","journal-title":"BMC Cancer"},{"key":"R8-20260426","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-20260426","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1378\/chest.09-2292","article-title":"A comprehensive review of spontaneous pneumothorax complicating sarcoma","volume":"138","author":"Hoag","year":"2010","journal-title":"Chest"},{"key":"R10-20260426","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-4-14","article-title":"Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: A single reference centre case series","volume":"4","author":"Verschoor","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"R11-20260426","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12885-018-4858-8","article-title":"Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study","volume":"18","author":"Sabath","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_95_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:10Z","timestamp":1786647250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_95_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_95_21","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"2021-01-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}